Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

A recent study conducted by an international team of scientists has revealed that the Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccine, AZD1222, is capable of inducing strong spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses in vaccinated individuals. A detailed description of AZD1222-induced cellular immunity is currently available on the medRxiv* preprint server.

28 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Long COVID has low prevalence in school-age children, UK study suggests

A new study, released as a preprint on the medRxiv* server, offers some insights into what may be expected in this field, how common it is, how it presents, and how it compares with chronic sequelae of other respiratory viruses.

24 Jun 2021

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

The SARS-CoV-2 virus and its vaccines pose unique challenges

Iranian researchers recently provided a review of the attempts made to develop safe SARS-CoV-2 vaccines. The researchers outlined potential challenges and concerns, including disease enhancement, virus mutation, and public acceptability. Their work is published in the journal Immunological Investigations.

18 Jun 2021

New insight into SARS-CoV-2 mRNA vaccine breakthrough infections

In the current study, vaccine breakthrough infections were noted in 24 people who had previously received COVID-19 vaccines.

17 Jun 2021

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.

17 Jun 2021

Study details the treatment of COVID-19 vaccine-associated myocarditis-like illness in 7 patients

Findings from a small study detailing the treatment of myocarditis-like symptoms in seven people after receiving a COVID-19 vaccine in the U.S. are published today in the American Heart Association’s flagship journal Circulation.

17 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

Researchers examine the importance of time after COVID-19 vaccination

A new study has been published on the medRxiv* preprint server, which deals with the importance of time post-vaccination based on the quantification of VOC immune evasion. The current study developed a toy model to estimate the effectiveness of the vaccines against VOC over time. Researchers have shown that the estimated value is highly dependent on time post-vaccination. Additionally, this model can describe the implications of changes in vaccine efficacy against VOC.

14 Jun 2021

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.

13 Jun 2021

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

A new study suggests that the rollout of vaccines against the COVID-19 pandemic may be significant not only in preventing infections by SARS-CoV-2 but other endemic and pandemic-potential coronaviruses (CoVs) as well.

10 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

The great promise of antiviral peptides against SARS-CoV-2

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

7 Jun 2021

Heterologous AstraZeneca and Pfizer vaccines induce strong immune response and T cell reactivity against multiple SARS-CoV-2 variants

Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.

3 Jun 2021

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

A team of scientists from France has recently conducted a study to evaluate the sensitivity of the B.1.617 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to antibody-mediated neutralization.

31 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Do mixed COVID-19 vaccines provide immunity?

The initial results of the CombivacS trial found that the antibody levels in individuals increased by 150 times when the Pfizer messenger ribonucleic acid (mRNA) vaccine was given after a first dose of the AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, with only mild common side effects.

24 May 2021

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Researchers in the UK have demonstrated the efficacy of the Pfizer-BioNTech and AstraZeneca vaccines against severe acute respiratory virus coronavirus 2 (SARS-CoV-2) at preventing death among older individuals with coronavirus disease 2019 (COVID-19).

20 May 2021

Adenovirus News and Research

Further Reading

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Long COVID has low prevalence in school-age children, UK study suggests

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

The SARS-CoV-2 virus and its vaccines pose unique challenges

New insight into SARS-CoV-2 mRNA vaccine breakthrough infections

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

Study details the treatment of COVID-19 vaccine-associated myocarditis-like illness in 7 patients

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Researchers examine the importance of time after COVID-19 vaccination

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

The great promise of antiviral peptides against SARS-CoV-2

Heterologous AstraZeneca and Pfizer vaccines induce strong immune response and T cell reactivity against multiple SARS-CoV-2 variants

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

Do mixed COVID-19 vaccines provide immunity?

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News